Literature DB >> 11163990

Inertial sizing of aerosol inhaled from two dry powder inhalers with realistic breath patterns versus constant flow rates.

W H Finlay1, M G Gehmlich.   

Abstract

A procedure is developed that allows particles inhaled with realistic breath patterns to be sized by cascade impaction at a constant flow rate. This procedure is then used to examine the difference between particle sizes obtained with constant flow rate (step profile) versus actual-subject breath patterns for two dry powder inhalers DPIs: the Ventodisk and Spiros inhalers (delivering salbutamol sulphate). Aerosol inhaled from the DPIs by a breath simulator was combined with make-up air to provide 300 l/min. to a pair of virtual impactors. These impactors separate out particles in the nominal diameter range of 1-10 microm for sizing at 30 l/min. by a MOUDI cascade impactor, with filter collection of particles outside this range. Breathing patterns of ten subjects ranging in age from 6 to 17 years of age were measured and recorded using whole-body plethysmography while these volunteers inhaled through Ventodisk and Spiros inhalers. Particle sizes with four of these breath patterns, as well as several constant flow rate step profiles, were then obtained using the sizing apparatus with a realistic mouth throat intake. Our results show that as long as the constant flow rates were near typical values occurring in the actual-subject breaths, particle sizes obtained with constant flow rates were not significantly different (P > 0.01) from those occurring with actual-subject breath patterns. Significant differences are present if constant flow rates unrepresentative of those expected during particle uptake with the actual-subject patterns are used with the Ventodisk. These results show that judiciously chosen constant flow rates give rise to inertial particle size measurements that are equivalent to those obtained during actual-subject inhalation for the two types of DPIs tested.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11163990     DOI: 10.1016/s0378-5173(00)00569-x

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  9 in total

1.  Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways.

Authors:  P Worth Longest; Geng Tian; Ross L Walenga; Michael Hindle
Journal:  Pharm Res       Date:  2012-06       Impact factor: 4.200

2.  Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations.

Authors:  Gary P Martin; Christopher Marriott; Xian-Ming Zeng
Journal:  Pharm Res       Date:  2006-12-20       Impact factor: 4.200

3.  Inhalation performance of physically mixed dry powders evaluated with a simple simulator for human inspiratory flow patterns.

Authors:  Daiki Hira; Tomoyuki Okuda; Daisuke Kito; Kazunori Ishizeki; Toyoko Okada; Hirokazu Okamoto
Journal:  Pharm Res       Date:  2010-07-14       Impact factor: 4.200

4.  Validating Whole-Airway CFD Predictions of DPI Aerosol Deposition at Multiple Flow Rates.

Authors:  P Worth Longest; Geng Tian; Navvab Khajeh-Hosseini-Dalasm; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-04-15       Impact factor: 2.849

5.  Comparison of in vitro deposition of pharmaceutical aerosols in an idealized child throat with in vivo deposition in the upper respiratory tract of children.

Authors:  Conor A Ruzycki; Laleh Golshahi; Reinhard Vehring; Warren H Finlay
Journal:  Pharm Res       Date:  2014-01-07       Impact factor: 4.200

6.  Using Filters to Estimate Regional Lung Deposition with Dry Powder Inhalers.

Authors:  Scott Tavernini; Dino J Farina; Andrew R Martin; Warren H Finlay
Journal:  Pharm Res       Date:  2021-08-31       Impact factor: 4.200

7.  Formulation of High-Performance Dry Powder Aerosols for Pulmonary Protein Delivery.

Authors:  Erin M Wilson; J Christopher Luft; Joseph M DeSimone
Journal:  Pharm Res       Date:  2018-08-23       Impact factor: 4.200

8.  Developing ways to evaluate in the laboratory how inhalation devices will be used by patients and care-givers: the need for clinically appropriate testing.

Authors:  Jolyon P Mitchell; Jason A Suggett
Journal:  AAPS PharmSciTech       Date:  2014-06-04       Impact factor: 3.246

9.  Spray-dried microparticles containing polymeric micelles encapsulating hematoporphyrin.

Authors:  Yu-Tsai Yang; Chin-Tin Chen; Jen-Chang Yang; Tsuimin Tsai
Journal:  AAPS J       Date:  2010-01-26       Impact factor: 4.009

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.